|
WO2015107139A1
|
|
Compounds for use as antifibrinolytic agents
|
|
WO2015104343A1
|
|
New antifibrinolytic compounds
|
|
WO2013190081A1
|
|
Methods and reagents for the prognosis of cancer
|
|
WO2013053765A1
|
|
A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
|
|
WO2012123269A1
|
|
Immunogenic compositions and methods for their use
|
|
EP2535049A1
|
|
Tadalafil for the treatment of dementia
|
|
WO2011154308A1
|
|
New compositions and cell therapy methods for the treatment of cirrhosis
|
|
MX2012009748A
|
|
Use of transforming growth factor - beta 1 (tgf-î²1) inhibitor peptides for the treatment of corneal fibrosis and/or haze.
|
|
WO2011101332A1
|
|
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
|
EP2535057A2
|
|
Compositions for the treatment of infectious and tumoural diseases
|
|
CA2780671A1
|
|
Regulated expression system
|
|
WO2011054990A2
|
|
Use of 5' -methylthioadenosine for the inhibition of the epithelial-mesenchymal transition
|
|
WO2012045894A1
|
|
Compounds and compositions for the treatment of illnesses caused by the hepatitis b virus
|
|
CN102316892A
|
|
Use of cardiotrophin- 1 for the treatment of metabolic diseases
|
|
WO2010063865A1
|
|
Use of phenol-soluble modulins for vaccine development
|
|
EP2305309A2
|
|
Conjugates for the administration of biologically active compounds
|
|
CN102131931A
|
|
Adaptive molecule for delivery of adenovirus vectors
|
|
BRPI0906657A2
|
|
Methods and compositions capable of synergistically causing post-transcriptional silencing of gene expression
|
|
ES2342529A1
|
|
ONCOSTATINA M AS POTENTIATOR OF THE IMMUNOSTIMULATING ACTIVITY OF HUMAN EPITHELIAL CELLS.
|
|
WO2009043953A1
|
|
Use of truncated ppar-alpha inhibitors in the treatment of heart failure in patients with hypertensive cardiopathy
|
